Mutations of these two residues to polar ones (L834R and L837E) have been found in lung cancer patients, and the EGFR kinase domain carrying the L834R mutation displays a substantially increased activity, underscoring the importance of the two residues in the inhibition of the kinase activity [37]. The gene discussed is EGFR; the disease is lung carcinoma.